Generation of a heterozygous GAPDH-Luciferase human ESC line (HVRDe008-A-1) for in vivo monitoring of stem cells and their differentiated progeny

Dario Gerace; Kyle R Boulanger; Jennifer Hyoje-Ryu Kenty; Douglas A Melton

doi:10.1016/j.scr.2021.102371

Generation of a heterozygous GAPDH-Luciferase human ESC line (HVRDe008-A-1) for in vivo monitoring of stem cells and their differentiated progeny

Stem Cell Res. 2021 May:53:102371. doi: 10.1016/j.scr.2021.102371. Epub 2021 Apr 27.

Authors

Dario Gerace¹, Kyle R Boulanger¹, Jennifer Hyoje-Ryu Kenty¹, Douglas A Melton²

Affiliations

¹ Department of Stem Cell and Regenerative Biology, Harvard University, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Boston MA, USA.
² Department of Stem Cell and Regenerative Biology, Harvard University, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Boston MA, USA. Electronic address: dmelton@harvard.edu.

PMID: 34088000
DOI: 10.1016/j.scr.2021.102371

Abstract

Human stem cell-derived beta (SC-β) cells are a candidate for cell replacement therapy for type 1 diabetes. Whilst refinements to the differentiation protocol have resulted in the production of SC-β cells that resemble adult beta cells, the unsolved challenge to protect transplanted SC-β cells from the host immune system remains. To monitor the survival of SC-β cells in vivo, we knocked-in the Firefly luciferase gene into the GAPDH locus of the HUES8 human embryonic stem cell (hESC) line, such that differentiated islet cells constitutively express luciferase.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Differentiation
Cell Line
Embryonic Stem Cells*
Humans
Insulin-Secreting Cells*
Luciferases

Substances

Luciferases

Grants and funding

HHMI/Howard Hughes Medical Institute/United States